{"transactions":[{"id":3530056,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":113074,"kind":"organization","name":"Takeda Ventures, Inc.","position":1,"cik":"0001771657","reported_name":"Takeda Ventures, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":3,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":4,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2019-05-13T19:52:46.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":319731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"Takeda USA\"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA.  Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":319731},"source":{"system":"sec-edgar","filing":"0001209191-19-029480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716229/000120919119029480/doc4.xml","form_type":"4"}},{"id":3530055,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":113074,"kind":"organization","name":"Takeda Ventures, Inc.","position":1,"cik":"0001771657","reported_name":"Takeda Ventures, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":3,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":4,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2019-05-13T19:52:46.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":2360071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"Takeda USA\"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA.  Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2360071},"source":{"system":"sec-edgar","filing":"0001209191-19-029480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716229/000120919119029480/doc4.xml","form_type":"4"}},{"id":3530054,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":113074,"kind":"organization","name":"Takeda Ventures, Inc.","position":1,"cik":"0001771657","reported_name":"Takeda Ventures, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":3,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":4,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:52:46.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":2679802,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are owned directly by Takeda Ventures, Inc. Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"Takeda USA\"). Takeda Pharmaceuticals International AG owns 41.91% of Takeda USA, and Takeda Pharmaceutical Company Limited owns 58.09% of Takeda USA.  Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited."}],"balance_after":2679802,"source":{"system":"sec-edgar","filing":"0001209191-19-029480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716229/000120919119029480/doc4.xml","form_type":"4"}},{"id":3986459,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168139,"kind":"person","name":"Takeda A/S","position":3,"cik":"0001716380","reported_name":"Takeda A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168140,"kind":"organization","name":"Takeda Europe Holdings B.V.","position":4,"cik":"0001716379","reported_name":"Takeda Europe Holdings B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168141,"kind":"person","name":"Takeda Pharma A/S","position":5,"cik":"0001716226","reported_name":"Takeda Pharma A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-21T21:42:49.000Z","date":"2018-03-19","kind":"purchase","acquired":true,"shares":7420625,"price":18.67,"value":138543068.75,"ownership":{"direct":false,"nature":"By Millennium\nPharmaceuticals\n, Inc."},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On March 19, 2018, Takeda Pharmaceuticals International AG (\"TPIZ\") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. (\"Millennium\"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC\"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) (\"TPAS\") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV\"); TPAS is owned by Takeda A/S (Denmark) (''T AS\"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 19, 2018, Takeda Pharmaceuticals International AG (\"TPIZ\") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. (\"Millennium\"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC\"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) (\"TPAS\") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV\"); TPAS is owned by Takeda A/S (Denmark) (''T AS\"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On March 19, 2018, Takeda Pharmaceuticals International AG (\"TPIZ\") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. (\"Millennium\"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC\"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) (\"TPAS\") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV\"); TPAS is owned by Takeda A/S (Denmark) (''T AS\"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein."}],"balance_after":7420625,"source":{"system":"sec-edgar","filing":"0000899243-18-008309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716380/000089924318008309/doc4.xml","form_type":"4"}},{"id":3986458,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":2,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168139,"kind":"person","name":"Takeda A/S","position":3,"cik":"0001716380","reported_name":"Takeda A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168140,"kind":"organization","name":"Takeda Europe Holdings B.V.","position":4,"cik":"0001716379","reported_name":"Takeda Europe Holdings B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":168141,"kind":"person","name":"Takeda Pharma A/S","position":5,"cik":"0001716226","reported_name":"Takeda Pharma A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-21T21:42:49.000Z","date":"2018-03-19","kind":"sale","acquired":false,"shares":7420625,"price":18.67,"value":138543068.75,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On March 19, 2018, Takeda Pharmaceuticals International AG (\"TPIZ\") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. (\"Millennium\"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC\"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) (\"TPAS\") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV\"); TPAS is owned by Takeda A/S (Denmark) (''T AS\"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 19, 2018, Takeda Pharmaceuticals International AG (\"TPIZ\") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. (\"Millennium\"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited (''TPC\"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) (\"TPAS\") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) (''TEHBV\"); TPAS is owned by Takeda A/S (Denmark) (''T AS\"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-008309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716380/000089924318008309/doc4.xml","form_type":"4"}},{"id":4349800,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Shares","published_at":"2017-04-19T16:12:08.000Z","date":"2017-04-17","kind":"exercise","acquired":false,"shares":4432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"$0.000017727 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":4432},"source":{"system":"sec-edgar","filing":"0001209191-17-027447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000120919117027447/doc4.xml","form_type":"4"}},{"id":4349799,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2017-04-19T16:12:08.000Z","date":"2017-04-17","kind":"exercise","acquired":true,"shares":4432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"$0.000017727 per share."}],"balance_after":7420625,"source":{"system":"sec-edgar","filing":"0001209191-17-027447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000120919117027447/doc4.xml","form_type":"4"}},{"id":4372663,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Shares","published_at":"2017-03-24T18:00:31.000Z","date":"2017-03-15","kind":"exercise","acquired":false,"shares":13091,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"$0.000017727 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":13091},"source":{"system":"sec-edgar","filing":"0001209191-17-022833","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000120919117022833/doc4.xml","form_type":"4"}},{"id":4372662,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Shares","published_at":"2017-03-24T18:00:31.000Z","date":"2017-02-15","kind":"exercise","acquired":false,"shares":6845,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"$0.000017727 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":6845},"source":{"system":"sec-edgar","filing":"0001209191-17-022833","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000120919117022833/doc4.xml","form_type":"4"}},{"id":4372661,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2017-03-24T18:00:31.000Z","date":"2017-03-15","kind":"exercise","acquired":true,"shares":13091,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"$0.000017727 per share."}],"balance_after":7416193,"source":{"system":"sec-edgar","filing":"0001209191-17-022833","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000120919117022833/doc4.xml","form_type":"4"}},{"id":4372660,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2017-03-24T18:00:31.000Z","date":"2017-02-15","kind":"exercise","acquired":true,"shares":6845,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"$0.000017727 per share."}],"balance_after":7403102,"source":{"system":"sec-edgar","filing":"0001209191-17-022833","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000120919117022833/doc4.xml","form_type":"4"}},{"id":4388844,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Shares","published_at":"2017-03-13T16:34:14.000Z","date":"2017-01-17","kind":"exercise","acquired":false,"shares":5727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"$0.000017727 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":5727},"source":{"system":"sec-edgar","filing":"0000904454-17-000243","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000090445417000243/edgar.xml","form_type":"4"}},{"id":4388843,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Shares","published_at":"2017-03-13T16:34:14.000Z","date":"2016-12-15","kind":"exercise","acquired":false,"shares":22141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"$0.000017727 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":22141},"source":{"system":"sec-edgar","filing":"0000904454-17-000243","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000090445417000243/edgar.xml","form_type":"4"}},{"id":4388842,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2017-03-13T16:34:14.000Z","date":"2017-01-17","kind":"exercise","acquired":true,"shares":5727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"$0.000017727 per share."}],"balance_after":7396257,"source":{"system":"sec-edgar","filing":"0000904454-17-000243","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000090445417000243/edgar.xml","form_type":"4"}},{"id":4388841,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2017-03-13T16:34:14.000Z","date":"2016-12-15","kind":"exercise","acquired":true,"shares":22141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"$0.000017727 per share."}],"balance_after":7390530,"source":{"system":"sec-edgar","filing":"0000904454-17-000243","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000090445417000243/edgar.xml","form_type":"4"}},{"id":4568102,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Shares","published_at":"2016-11-03T16:49:23.000Z","date":"2016-11-01","kind":"exercise","acquired":false,"shares":1977269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"$0.000017727 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":1977269},"source":{"system":"sec-edgar","filing":"0001209191-16-148209","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000120919116148209/doc4.xml","form_type":"4"}},{"id":4568101,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":157677,"kind":"organization","name":"Takeda Pharmaceuticals International AG","position":1,"cik":"0001688140","reported_name":"Takeda Pharmaceuticals International AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2016-11-03T16:49:23.000Z","date":"2016-11-01","kind":"exercise","acquired":true,"shares":1977269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"$0.000017727 per share."}],"balance_after":7368389,"source":{"system":"sec-edgar","filing":"0001209191-16-148209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688140/000120919116148209/doc4.xml","form_type":"4"}}]}